These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29153696)

  • 1. Dysregulation of circulating autoantibodies against VEGF-A, VEGFR-1 and PlGF in preeclampsia - A role in placental and vascular health?
    Moe K; Heidecke H; Dechend R; Staff AC
    Pregnancy Hypertens; 2017 Oct; 10():83-89. PubMed ID: 29153696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
    Govender N; Naicker T; Rajakumar A; Moodley J
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?
    Bdolah Y; Lam C; Rajakumar A; Shivalingappa V; Mutter W; Sachs BP; Lim KH; Bdolah-Abram T; Epstein FH; Karumanchi SA
    Am J Obstet Gynecol; 2008 Apr; 198(4):428.e1-6. PubMed ID: 18191808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia.
    Sahay AS; Patil VV; Sundrani DP; Joshi AA; Wagh GN; Gupte SA; Joshi SR
    Hypertens Res; 2014 Aug; 37(8):753-8. PubMed ID: 24718301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences.
    Tsatsaris V; Goffin F; Munaut C; Brichant JF; Pignon MR; Noel A; Schaaps JP; Cabrol D; Frankenne F; Foidart JM
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5555-63. PubMed ID: 14602804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal plasma VEGF, sVEGF-R1, and PlGF concentrations in preeclamptic and normotensive pregnant Zimbabwean women.
    Muy-Rivera M; Vadachkoria S; Woelk GB; Qiu C; Mahomed K; Williams MA
    Physiol Res; 2005; 54(6):611-22. PubMed ID: 15717861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
    Aggarwal PK; Chandel N; Jain V; Jha V
    J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating angiogenic factors and the risk of preeclampsia.
    Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
    N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia.
    Ahmad S; Ahmed A
    Circ Res; 2004 Oct; 95(9):884-91. PubMed ID: 15472115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin.
    Bujold E; Romero R; Chaiworapongsa T; Kim YM; Kim GJ; Kim MR; Espinoza J; Gonçalves LF; Edwin S; Mazor M
    J Matern Fetal Neonatal Med; 2005 Jul; 18(1):9-16. PubMed ID: 16105786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating levels of angiogenic factors and their association with preeclampsia among pregnant women at Mulago National Referral Hospital in Uganda.
    Nabweyambo S; Sande OJ; McGovern N; Bwanga F; Ssekagiri A; Keesiga A; Adroma M; Wasswa R; Atuheirwe M; Namugenyi J; Castelnuovo B; Nakimuli A
    PLoS One; 2021; 16(5):e0251227. PubMed ID: 34010327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Different effects of pravastatin on sFlt-1, PlGF and VEGF in different preeclampsia-like mouse models].
    Xiang QQ; Yang Z; Huai J; Wang GJ
    Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):601-607. PubMed ID: 31550776
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.
    Soto E; Romero R; Kusanovic JP; Ogge G; Hussein Y; Yeo L; Hassan SS; Kim CJ; Chaiworapongsa T
    J Matern Fetal Neonatal Med; 2012 May; 25(5):498-507. PubMed ID: 21867402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
    Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
    Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies.
    Dröge L; Herraìz I; Zeisler H; Schlembach D; Stepan H; Küssel L; Henrich W; Galindo A; Verlohren S
    Ultrasound Obstet Gynecol; 2015 Mar; 45(3):286-93. PubMed ID: 25491901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.